-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to statistics, as of April 29, 2022, a total of 3,841 companies in the A-share market have disclosed their results for the first quarter of 2022.
Among them, 1,511 companies have social security funds, pensions, QFII, etc.
There are five major institutions including securities companies and insurance companies
.
It is worth noting that pharmaceutical biology is one of the fields that are generally favored and focused by the five major institutions in the first quarter of this year
.
Analysts pointed out that the joint positions of social security funds and pensions have also attracted investors' attention
.
According to sorting out, 57 stocks are jointly held by the above two major institutions, and 15 stocks including Renfu Medicine and others have held more than 10 million shares
.
It is understood that Renfu Pharmaceutical has made a good start in the first quarter of 2022, achieving a year-on-year increase of 10.
5% in operating income to 5.
16 billion; the net profit attributable to the parent has increased by 210% year-on-year to 930 million yuan
.
In addition, the annual report of Renfu Medicine in 2021 is also very interesting.
In 2021, the annual operating income of 20.
441 billion yuan will be realized, the operating income will exceed 20 billion yuan for the third consecutive year, and the net profit attributable to shareholders of the listed company will be 1.
390 billion yuan, a year-on-year increase.
Nearly 21%, in addition, deducted non-net profit increased by 41.
39% to 1.
078 billion yuan
.
Renfu Medicine has been established for 30 years.
The company's products include generic drugs, innovative preparations and innovative drugs with high clinical value
.
Benefiting from the efficient implementation of the company's "return to core and focus" strategy, the company's performance has achieved high-quality growth
.
It is reported that in the process of development, Renfu Medicine adheres to independent research and development, integrates internal research and development resources, and builds a core research and development team and technology platform; it continues to increase research and development investment.
From 2019 to 2021, your company's research and development investment will be 760 million yuan and 940 million yuan respectively.
RMB 1.
05 billion, accounting for more than 10% of the company's pharmaceutical industry revenue, and the annual growth of R&D investment is more than 10%
.
Among the stocks newly acquired and increased by the five major institutions, a total of 143 stocks have a dynamic price-earnings ratio lower than the new A-share price-earnings ratio (15.
47 times as of April 29), which can be said to meet the standards of low-value stocks
.
Specifically, there are 63 stocks with a new dynamic price-earnings ratio of less than 10 times, of which 8 stocks, including Anxu Bio (3.
39 times) and Rejing Bio (3.
78 times), have a new dynamic price-earnings ratio of less than 5 times
.
It is understood that in the first quarter of 2022, Anxu Bio achieved a year-on-year increase of 2763.
42% in revenue to 5.
474 billion yuan; net profit attributable to the parent increased by 3147.
87% year-on-year to 2.
682 billion yuan
.
In addition, in 2021, Anxu Bio achieved revenue of 1.
589 billion yuan, a year-on-year increase of 32.
47%; net profit attributable to the parent was 738.
5 million yuan, a year-on-year increase of 13.
8%
.
In the first quarter of 2022, Rejing Bio achieved an operating income of 1.
364 billion yuan, a year-on-year increase of 11.
14%, and a net profit of 606 million yuan, a year-on-year increase of 0.
77%
.
In 2021, the company achieved revenue of 5.
369 billion yuan, a year-on-year increase of 945.
54%; net profit attributable to the parent was 2.
186 billion yuan, a year-on-year increase of 1850.
41
.
In addition, compared with 2021, among the 412 stocks held by the social security fund, 214 stocks have become the newly increased holdings of the social security fund in the first quarter of this year, involving 28 Shenwan first-tier industries
.
Among them, there are 24 pharmaceutical and biological stocks; among the 644 QFII holding stocks, 414 individual stocks have become the newly increased QFII holdings in the first quarter of this year, involving 31 Shenwan primary industries
.
Among them, there are 59 medical organisms, which are still optimistic
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
Among them, 1,511 companies have social security funds, pensions, QFII, etc.
There are five major institutions including securities companies and insurance companies
.
It is worth noting that pharmaceutical biology is one of the fields that are generally favored and focused by the five major institutions in the first quarter of this year
.
Analysts pointed out that the joint positions of social security funds and pensions have also attracted investors' attention
.
According to sorting out, 57 stocks are jointly held by the above two major institutions, and 15 stocks including Renfu Medicine and others have held more than 10 million shares
.
It is understood that Renfu Pharmaceutical has made a good start in the first quarter of 2022, achieving a year-on-year increase of 10.
5% in operating income to 5.
16 billion; the net profit attributable to the parent has increased by 210% year-on-year to 930 million yuan
.
In addition, the annual report of Renfu Medicine in 2021 is also very interesting.
In 2021, the annual operating income of 20.
441 billion yuan will be realized, the operating income will exceed 20 billion yuan for the third consecutive year, and the net profit attributable to shareholders of the listed company will be 1.
390 billion yuan, a year-on-year increase.
Nearly 21%, in addition, deducted non-net profit increased by 41.
39% to 1.
078 billion yuan
.
Renfu Medicine has been established for 30 years.
The company's products include generic drugs, innovative preparations and innovative drugs with high clinical value
.
Benefiting from the efficient implementation of the company's "return to core and focus" strategy, the company's performance has achieved high-quality growth
.
It is reported that in the process of development, Renfu Medicine adheres to independent research and development, integrates internal research and development resources, and builds a core research and development team and technology platform; it continues to increase research and development investment.
From 2019 to 2021, your company's research and development investment will be 760 million yuan and 940 million yuan respectively.
RMB 1.
05 billion, accounting for more than 10% of the company's pharmaceutical industry revenue, and the annual growth of R&D investment is more than 10%
.
Among the stocks newly acquired and increased by the five major institutions, a total of 143 stocks have a dynamic price-earnings ratio lower than the new A-share price-earnings ratio (15.
47 times as of April 29), which can be said to meet the standards of low-value stocks
.
Specifically, there are 63 stocks with a new dynamic price-earnings ratio of less than 10 times, of which 8 stocks, including Anxu Bio (3.
39 times) and Rejing Bio (3.
78 times), have a new dynamic price-earnings ratio of less than 5 times
.
It is understood that in the first quarter of 2022, Anxu Bio achieved a year-on-year increase of 2763.
42% in revenue to 5.
474 billion yuan; net profit attributable to the parent increased by 3147.
87% year-on-year to 2.
682 billion yuan
.
In addition, in 2021, Anxu Bio achieved revenue of 1.
589 billion yuan, a year-on-year increase of 32.
47%; net profit attributable to the parent was 738.
5 million yuan, a year-on-year increase of 13.
8%
.
In the first quarter of 2022, Rejing Bio achieved an operating income of 1.
364 billion yuan, a year-on-year increase of 11.
14%, and a net profit of 606 million yuan, a year-on-year increase of 0.
77%
.
In 2021, the company achieved revenue of 5.
369 billion yuan, a year-on-year increase of 945.
54%; net profit attributable to the parent was 2.
186 billion yuan, a year-on-year increase of 1850.
41
.
In addition, compared with 2021, among the 412 stocks held by the social security fund, 214 stocks have become the newly increased holdings of the social security fund in the first quarter of this year, involving 28 Shenwan first-tier industries
.
Among them, there are 24 pharmaceutical and biological stocks; among the 644 QFII holding stocks, 414 individual stocks have become the newly increased QFII holdings in the first quarter of this year, involving 31 Shenwan primary industries
.
Among them, there are 59 medical organisms, which are still optimistic
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
